Deutsch English Français

Contact

EP3522881

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3522881

EP3522881 - HIGH MOBILITY GROUP B1 PROTEIN INHIBITORS [Right-click to bookmark this link]
Status	The application is deemed to be withdrawn Status updated on 03.04.2021 Database last updated on 03.10.2024
Former	Request for examination was made Status updated on 12.07.2019
Former	The international publication has been made Status updated on 14.04.2018
Most recent event Tooltip	03.04.2021	Application deemed to be withdrawn	published on 05.05.2021 [2021/18]
Applicant(s)	For all designated states Afecta Pharmaceuticals, Inc. 2102 Business Center Drive Irvine, CA 92612 / US
	[2019/33]
Inventor(s)	01 / KOVACS, Bruce 2102 Business Center Drive Irvine California 92612 / US
	02 / SHAHBAHRAMI, Kamron 17 Foxhill Irvine California 92604 / US
	03 / NICOLA, George 8288 Gilman Dr. Unit 43 La Jolla, CA 92037 / US
	[2019/34]
Former [2019/33]	01 / KOVACS, Bruce 2102 Business Center Drive Irvine California 92612 / US
	02 / SHAHBAHRAMI, Kamron 17 Foxhill Irvine California 92604 / US
	03 / NICOLA, George 2102 Business Center Drive Irvine California 92612 / US
Representative(s)	Elsy, David Withers & Rogers LLP 2 London Bridge London SE1 9RA / GB
	[N/P]
Former [2019/33]	Elsy, David Withers & Rogers LLP 4 More London Riverside London SE1 2AU / GB
Application number, filing date	17859072.5	04.10.2017
	[2019/33]
	WO2017US55041
Priority number, date	US201662404508P	05.10.2016 Original published format: US 201662404508 P
	[2019/33]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2018067638
	Date:	12.04.2018
	Language:	EN
	[2018/15]
	Type:	A2 Application without search report
	No.:	EP3522881
	Date:	14.08.2019
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 12.04.2018 takes the place of the publication of the European patent application.
	[2019/33]
Search report(s)	International search report - published on:	US	23.05.2019
	(Supplementary) European search report - dispatched on:	EP	28.04.2020
Classification	IPC:	C07C235/10, C07D295/13, A61K31/195, A61K31/165, A61K45/06, A61P29/00	[2020/22]
	CPC:	A61K31/165 (EP); C07C233/08 (US); A61K31/195 (EP); A61K45/06 (EP); C07C229/38 (US); C07C235/10 (EP); (+) C07D295/13 (EP); Y02A50/30 (EP) (-)
	Former IPC [2019/33]	A61K31/195, A61K31/165
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/33]
Title	German:	HOCHMOBILE GRUPPE-B1-PROTEIN-INHIBITOREN	[2019/33]
	English:	HIGH MOBILITY GROUP B1 PROTEIN INHIBITORS	[2019/33]
	French:	INHIBITEURS DE PROTÉINE DU GROUPE B1 À MOBILITÉ ÉLEVÉE	[2019/33]
Entry into regional phase	02.04.2019	National basic fee paid
	02.04.2019	Search fee paid
	02.04.2019	Designation fee(s) paid
	02.04.2019	Examination fee paid
Examination procedure	02.04.2019	Examination requested [2019/33]
	10.05.2019	Amendment by applicant (claims and/or description)
	26.11.2020	Application deemed to be withdrawn, date of legal effect [2021/18]
	16.12.2020	Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2021/18]
Fees paid	Renewal fee
	10.10.2019	Renewal fee patent year 03
	Penalty fee
	Additional fee for renewal fee
	31.10.2020	04 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[Y]US2004053841 (TRACEY KEVIN J [US], et al) [Y] 1-15 * figure 4a * * paragraph [0008] * * paragraphs [0067] - [0088] *;
		[Y]US2008317809 (FUMERO SILVANO [IT], et al) [Y] 1-15 * paragraph [0010] ** claims *;
		[XY] - MARÍA GÁLVEZ-LLOMPART ET AL, "Selection of nutraceutical compounds as COX inhibitors by molecular topology", MEDICINAL CHEMISTRY RESEARCH., US, (20121123), vol. 22, no. 7, doi:10.1007/s00044-012-0361-y, ISSN 1054-2523, pages 3466 - 3477, XP055116300 [X] 1,2,4-7,9 * abstract * * page 3469, table 1: "Mefexamide" * [Y] 1-15 DOI: http://dx.doi.org/10.1007/s00044-012-0361-y
	International search	[Y]US2004053841 (TRACEY KEVIN J [US], et al) [Y] 4-6* ; figure 4A; paragraphs [0008], [0087]-[0088] *;
		[Y]US2006205980 (HANAZAWA TAKESHI [JP], et al) [Y] 1-8 * ; paragraph [0006] *;
		[Y]US2008045513 (DASSE OLIVIER [US]) [Y] 1-8 * ; paragraphs [0005], [0009], [0055]-[0056], [0058]-[0059], [0069], [0079], [0130], [0144] *;
		[X] - Anonymous, "N-(Aminomethyl)-2-phenoxyacetamide", PUBCHEM Compound, (20071205), Database accession no. CID 23103273, URL: NCBI, XP055611477 [X] 1 * >; page 3, formula *

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 35p